Literature DB >> 31448522

Pregnancy-associated breast cancer in a contemporary cohort of newly diagnosed women.

Jessica C Gooch1,2, Jennifer Chun1, Elianna Kaplowitz1, Amber Guth1, Deborah Axelrod1, Richard Shapiro1, Daniel Roses1, Freya Schnabel1.   

Abstract

Pregnancy-associated breast cancer (PABC) refers to breast cancer (BC) diagnosed during pregnancy, lactation, or in the postpartum period. There is evidence that PABC is associated with a poorer prognosis, and that the development of the disease is influenced by the unique hormonal milieu of pregnancy. The purpose of this study was to investigate the clinicopathologic characteristics associated with PABC in a contemporary cohort of women with newly diagnosed BC. Our institutional Breast Cancer Database was queried for women diagnosed with BC between 2009-2018 who had at least one full-term pregnancy (FTP). Variables of interest included patient demographics and clinical and tumor characteristics. PABC was defined as breast cancer diagnosed within 24 months of delivery. Statistical analyses included Pearson's chi-square and logistic regression. Out of a total of 2202 women, 46 (2.1%) had PABC. Median follow-up in the total cohort was 5.5 years. After adjusting for age at first FTP, PABC was associated with younger age at diagnosis, older age at first FTP, non-Caucasian race, BRCA positivity, presentation with a palpable mass, higher pathologic stage, higher histologic grade, and ER-negative and triple-negative receptor status. The association of PABC with non-Caucasian race may be reflected in the increased proportion of triple-negative breast cancers in the PABC group. PABC was also associated with older age at first FTP. As more women delay childbearing, risk for PABC may increase. Our findings suggest that women who become pregnant at older ages should be followed carefully during pregnancy and the postpartum period, especially if they are BRCA mutation carriers. The optimal approach for monitoring older women during pregnancy and the postpartum period is unclear.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; pregnancy

Mesh:

Year:  2019        PMID: 31448522     DOI: 10.1111/tbj.13510

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  5 in total

1.  Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.

Authors:  Katarzyna J Jerzak; Nechama Lipton; Sharon Nofech-Mozes; Dina Boles; Elzbieta Slodkowska; Gregory R Pond; Ellen Warner
Journal:  Breast Cancer Res Treat       Date:  2021-07-27       Impact factor: 4.872

2.  Germline mutations in a clinic-based series of pregnancy associated breast cancer patients.

Authors:  Eleni Zografos; Anna-Maria Korakiti; Angeliki Andrikopoulou; Ioannis Rellias; Constantine Dimitrakakis; Spyridon Marinopoulos; Aris Giannos; Antonios Keramopoulos; Nikolaos Bredakis; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  BMC Cancer       Date:  2021-05-19       Impact factor: 4.430

Review 3.  Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells.

Authors:  Prerana Muralidhara; Vanshika Sood; Vishnu Vinayak Ashok; Kushagra Bansal
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

4.  Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.

Authors:  Elham Sajjadi; Konstantinos Venetis; Marianna Noale; Hatem A Azim; Concetta Blundo; Giuseppina Bonizzi; Eugenia Di Loreto; Giovanna Scarfone; Stefano Ferrero; Stefania Maggi; Massimo Barberis; Paolo Veronesi; Viviana E Galimberti; Giuseppe Viale; Nicola Fusco; Fedro A Peccatori; Elena Guerini-Rocco
Journal:  Cells       Date:  2022-07-24       Impact factor: 7.666

5.  Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China.

Authors:  Bo-Yue Han; Xiao-Guang Li; Hai-Yun Zhao; Xin Hu; Hong Ling
Journal:  BMC Cancer       Date:  2020-03-23       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.